Brendan Teehan - 06 Jan 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
06 Jan 2024
Transactions value $
-$21,901
Form type
4
Filing time
09 Jan 2024, 18:00:33 UTC
Previous filing
21 Nov 2023
Next filing
27 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +1.29K +4.23% 31.7K 06 Jan 2024 Direct F1
transaction ACAD Common Stock Sale -$21.9K -731 -2.31% $29.96 30.9K 08 Jan 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -1.29K -100% $0.00* 0 06 Jan 2024 Common Stock 1.29K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.61 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024.